Key result
Only ~57% of obstructive HCM drug prescriptions align with ESC guidelines in real-world practice.
Why the study?
Despite clear ESC guideline-directed medical therapy recommendations for obstructive hypertrophic cardiomyopathy, real-world alignment with these guidelines remained unclear.
Cohort (n=1,141)
This study demonstrates substantial non-adherence to ESC guidelines in the real-world management of obstructive HCM in Germany, highlighting frequent use of contraindicated medications and the need for improved clinician education.
Answers are grounded in this paper and cite their sources.
Guideline non-adherence appears common in obstructive HCM; leaves open whether education improves alignment or outcomes.
Background: Obstructive hypertrophic cardiomyopathy (HCM) is defined by left ventricular hypertrophy with outflow tract obstruction. Despite clear guideline-directed medical therapy recommendations from the European Society of Cardiology (ESC), it remains unclear whether real-world treatment aligns with these guidelines. This study evaluates adherence to ESC guidance in Germany, focusing on pharmacological and invasive therapies and identifying gaps in real-world care for patients with obstructive HCM. Methods: A retrospective cohort analysis was conducted using the WIG2 Benchmark database, containing administrative claims data from German statutory health insurers. Patients aged ≥18 years who received an International Classification of Diseases (ICD)-coded diagnosis of HCM between 2012 and 2018 were included. Treatment alignment was assessed against ESC guidelines on HCM. Results: Of 6793 patients with an HCM diagnosis, 1141 had obstructive HCM. Mean age was 59.7 years and 62% were male. Following initial HCM consultation, 18% received beta-blocker (BB) monotherapy and 12% received calcium channel blocker (CCB) monotherapy, in accordance with ESC guidelines. However, 43% of treatment combinations were not aligned with the ESC guidelines, including use of contraindicated dihydropyridine CCBs and vasodilating BBs, and 22% of patients did not receive any HCM-related pharmacological treatment. Overall, only 57% of the prescribed treatments were consistent with ESC guidelines for obstructive HCM management. Conclusions: This study reveals substantial gaps in alignment with the ESC guidelines for obstructive HCM management in Germany, underscoring the need for enhanced clinician education on existing therapies. Greater uptake of guideline-directed medical therapy is critical to improving patient well-being, functional status and outcomes.
No takes yet. Share an insight, caveat, or question.
Sedaghat‐Hamedani et al. (2026) conducted a cohort in Obstructive Hypertrophic Cardiomyopathy (n=1,141). Pharmacological treatments for obstructive HCM vs. Non-guideline aligned treatments was evaluated on Alignment of prescribed pharmacological treatments with ESC guidelines for obstructive HCM. In a real-world German cohort, only 57% of prescribed pharmacological treatments for obstructive hypertrophic cardiomyopathy aligned with ESC guidelines, and 22% of patients received no treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: